- Vouliez-vous dire
- vaccines effectiveness
Résultats de la recherche - 4 results
Linkage of individual-patient data confirm protection of prophylactic human papillomavirus vaccination against invasive cervical cancer
papillomavirus (HPV) vaccine (Cervarix, GSK, Rixensart, Belgium) (1). The study completes and strengthens the evidence of the high level of effectiveness of primary cervical cancer prevention by HPV vaccination ...
The European response to the WHO call cervical cancer as a public health problem
should, by 2030, reach at least 90% HPV vaccine coverage among girls by the age of 15 years and also boys, if cost‐effective; they should introduce organised population‐based HPV ‐based screening and ...
Tackling cervical cancer in Europe amidst the COVID-19 pandemic.
estimates for 2018, approximately 33 000 cases of cervical cancer occurred and 15 000 people died from the disease in Europe (see map in appendix). Human papillomavirus (HPV) vaccine coverage is relatively ...
Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
antibodies against the vaccine HPV types). We will assess clinical effectiveness by evaluating outcomes in all women, irrespective of the HPV DNA or serology status at enrolment. Evaluation by fine age and ...